Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
RXRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.79 - $12.36
Previous CloseN/A
Volume5.68M
Average Volume (3M)29.38M
Market Cap
$2.45B
Enterprise Value$1.72B
Total Cash (Recent Filing)$500.45M
Total Debt (Recent Filing)$92.91M
Price to Earnings (P/E)―
Beta3.33
Next Earnings
Aug 05, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding425,280,640
10 Day Avg. Volume31,102,101
30 Day Avg. Volume29,381,138
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue28.78
Enterprise Value/Gross Profit-37.39K
Enterprise Value/Ebitda-3.22
Forecast
1Y Price Target
$6.25Price Target Upside10.04% Upside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Partnership SuccessPartnerships appear to be progressing well, with another $7M milestone received from Sanofi and potential for $300M for the program.
Pipeline FocusThe re-focusing of the pipeline is seen as a net positive that should help the market narrow in on key data sets.
Strategic AcquisitionRecursion acquired full rights to Rallybio's REV102, a preclinical oral ENPP1 inhibitor for hypophosphatasia, which could provide a strategic advantage.
Bears Say
Cash Burn ConcernsElevated cash burn and dilutive financing are concerning despite the potential for positive surprises from collaboration milestones.
Program DeprioritizationThe discontinuation of the NF2, CCM, and C. difficile programs reflects a cut in the most advanced assets in the portfolio.
Workforce ReductionRecursion announced a ~20% workforce reduction.
Recursion Pharmaceuticals News
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $3.79 and its highest was $12.36 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Recursion Pharmaceuticals’s market cap is $2.45B.
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is Aug 05, 2025 which is today.
How were Recursion Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -0.35.
How many shares outstanding does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 425,280,640 shares outstanding.
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Currently, no hedge funds are holding shares in RXRX
Recursion Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.25 (10.04% Upside)
$6.25 (10.04% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 87%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 8.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.61%
12-Months-Change
Fundamentals
Return on Equity
-86.10%
Trailing 12-Months
Asset Growth
133.98%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals (RXRX) is a biotechnology company that leverages advanced computational technology and experimental biology to discover and develop new treatments for various diseases. The company operates at the intersection of technology and biology, focusing on the use of artificial intelligence and machine learning to accelerate drug discovery. Their platform integrates high-throughput biology, artificial intelligence, and automation to efficiently identify potential therapies across multiple therapeutic areas.
RXRX Company Deck
RXRX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a balanced sentiment. While Recursion highlighted strong financials, successful platform evolution, and significant partnerships, they also faced challenges with program discontinuations and limited success in certain trials. The company's focus on pipeline advancements and strategic partnerships suggests a cautiously optimistic outlook.Read More>RXRX Stock 12 Month Forecast
Average Price Target
$6.25
▲(10.04%Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Harmony Biosciences Holdings
―
NewAmsterdam Pharma Company
―
Metsera, Inc.
―
Ownership Overview
3.66% Insiders
11.51% Mutual Funds
0.03% Other Institutional Investors
63.64% Public Companies and Individual Investors